What is it about?
In this manuscript we describe the development and validation of a novel 26 gene biomarker assay / gene expression screen that is able to measure drug-dependent modulation of an activated Ras-MAPK pathway in vitro, with the larger objective of identifying novel therapeutics for colon cancer.
Featured Image
Why is it important?
The gene biomarker assay does not require prior knowledge of the molecular targets which potentially enables novel target identification. Furthermore it can be adapted to cell lines representing other cancers that are dependent on activated Ras-MAPK pathway
Perspectives
The assay was observed to be very robust and validation of the screen was successful in that highly active “hit” compounds were enriched for those targeting preclinically and clinically validated proteins such as EGFR, MEK1,2 and Src.
Bryan M Severyn
Merck & Co., Inc
Read the Original
This page is a summary of: Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context, SLAS DISCOVERY, October 2016, SAGE Publications,
DOI: 10.1177/1087057116658646.
You can read the full text:
Resources
Contributors
The following have contributed to this page
